I shared a series of X posts in October 2026 about the emerging oral hair‑loss drug Veradermics is developing. The thread covered the historical precedent of minoxidil, off‑label use, trial results, safety, commercial potential, and our regulatory and pricing decisions.
Historical precedent: 60–80 % of Loniten users reported new facial/arm hair.
Off‑label use: a Melbourne dermatologist reported regrowth in 100 consecutive female patients.
Trial participants: 536 men were enrolled in a 6‑month double‑blind study.
Mean hair‑count increase: 36.4 hairs / cm² (treatment) vs 6.6 hairs / cm² (placebo).
Patient‑reported improvement: 69 % of treated participants said their hair looked better vs 15 % on placebo.
Safety: no serious drug‑related adverse events or flagged heart problems were reported.
Commercial potential: the company valuation exceeds $5 billion.
Pricing: $15 a month.
Regulatory strategy: we are pursuing FDA approval for the oral indication to unlock TV advertising and a larger market share.
First new oral hair‑loss pill since Propecia back in 1997.
First version of minoxidil anyone can legally put in a TV commercial.